Prescient Therapeutics Ltd (PTX) Stock Price & News

Prescient Therapeutics is a clinical-stage oncology company developing targeted therapies. Prescient's technologies emanate from prestigious world class centres including Yale, Penn, Oxford and Moffitt. Wikipedia

About Prescient Therapeutics Ltd

CEOSteven Yatomi-Clarke

Employees3

FoundedMay 22, 1986

Headquarters-

SectorHealth Care

IndustryBiotechnology

Websiteptxtherapeutics.com

All values in AUD	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	578.89K	578.89K	1.15M	1.15M
Cost of goods sold	-	-	-	-
Cost of revenue	-	-	-	-
Research and development expenses	1.24M	1.24M	1.40M	1.40M
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	1.13M	1.13M	1.20M	1.20M
Operating expense	2.57M	2.57M	2.73M	2.73M
Total operating expenses	2.57M	2.57M	2.73M	2.73M
Operating income	-1.99M	-1.99M	-1.58M	-1.58M
Other non operating income	-	-	-	-
EBT including unusual items	-1.99M	-1.99M	-1.51M	-1.51M
EBT excluding unusual items	-1.99M	-1.99M	-1.51M	-1.51M
Income tax expense	-	-	-	-
Effective tax rate	-	-	-	-
Other operating expenses	-	-	-	-
Net income	-1.99M	-1.99M	-1.51M	-1.51M
Net profit margin	-344.35%	-344.35%	-131.51%	-131.51%
Earnings per share	-	-	-	-
Interest and investment income	1.86K	1.86K	67.39K	67.39K
Interest expense	-2.97K	-2.97K	-2.38K	-2.38K
Net interest expenses	-1.12K	-1.12K	65.02K	65.02K
Depreciation and amortization charges	-	-	-	-
EBITDA	-	-	-	-1.55M
Gain or loss from assets sale	-	-	-	-

Ask anything